telcagepant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Telcagepant (INN) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co.   Wikipedia

Chemistry

  • SMILES: Oc1nc2ncccc2n1C3CCN(CC3)C(=O)N[C@@H]4CC[C@H](CN(CC(F)(F)F)C4=O)c5cccc(F)c5F
  • InChIKey: CGDZXLJGHVKVIE-DNVCBOLYSA-N
  • Mol. Mass: 566.53
  • ALogP: 4.1
  • ChEMBL Molecule:
    telcagepant  
More Chemistry

Pharmacology

Alternative names

mk0974 | mk 0974 | mk-0974 | n-((3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1h-azepin-3- yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide | n-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide | talcagepant | tecagepant | telcagepant

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Angina Pectoris (Phase 1)

Calcitonin Gene-Related Peptide (Phase 1)

Coronary Disease (Phase 1)

Heart Diseases (Phase 3)

Ischemic Attack, Transient (Phase 3)

Migraine Disorders (Phase 3)

Peripheral Vascular Diseases (Phase 3)

Stroke (Phase 3)

Vascular Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue